Inhibition of naive Th1 CD4+ T cells by glatiramer acetate in multiple sclerosis

Journal of Neuroimmunology

Volumn 185, Issue 1-2, 2007, Pages 123-129

  Kantengwa, S ^a   Weber, M S ^b   Juillard, C ^a   Benkhoucha, M ^a,c   Fellay, B ^d   Zamvil, S S ^b   Gougeon, M L ^e   Chofflon, M ^a   Lalive, P H ^a,c  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d Department of Chemistry and Haematology   (Switzerland)

^e Biotherapy and Vaccine Unit   (France)

Author keywords

CD4+ T cell; CD8+ T cell; Glatiramer acetate; Multiple sclerosis; T cell differentiation

Indexed keywords

GLATIRAMER; INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MATURATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; EFFECTOR CELL; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE DIFFERENTIATION; MALE; MULTIPLE SCLEROSIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TH1 CELL;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2; MALE; MULTIPLE SCLEROSIS; PEPTIDES; TH1 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33947665035     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2006.12.014     Document Type: Article

References (45)

1. Aharoni R., Kayhan B., Eilam R., Sela M., and Arnon R. Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factor in situ. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 14157-14162
2. Azoulay D., Vachapova V., Shihman B., Miler A., and Karni A. Lower brain-derived neurotrophic factor in serum of relapsing remitting MS: reversal by glatiramer acetate. J Neuroimmunol. 167 (2005) 215-218
3. Baars P.A., Maurice M.M., Repe M., Hooibrink B., and van Lier R.A. Heterogeneity of the circulating human CD4+ T cell population. Further evidence that the CD4+CD45RA-CD27- T cell subset contains specialized primed T cells. J. Immunol. 154 (1995) 17-25
4. Bitsch A., Kuhlmann T., Da Costa C., Bunkowski S., Polak T., and Bruck W. Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions: correlation with demyelinating activity and oligodendrocyte pathology. Glia 29 (2000) 366-375
5. Burns J., Bartholomew B., and Lobo S. Isolation of myelin basic protein-specific T cells predominantly from the memory T-cell compartment in multiple sclerosis. Ann. Neurol. 45 (1999) 33-39
6. Chofflon M., and Fellay B. Monitoring multiple sclerosis course and activity with TNF-alpha. Mult. Scler. 4 (1998) 188-192
7. Clerici M., Saresella M., Trabattoni D., Speciale L., Fossati S., Ruzzante S., Cavaretta R., Filippi M., Caputo D., and Ferrante P. Single-cell analysis of cytokine production shows different immune profiles in multiple sclerosis patients with active or quiescent disease. J. Neuroimmunol. 121 (2001) 88-101
8. Duda P.W., Schmied M.C., Cook S.L., Krieger J.I., and Hafler D.A. Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J. Clin. Invest. 105 (2000) 967-976
9. Duszczyszyn D.A., Beck J.D., Antel J., Bar-Or A., Lapierre Y., Gadag V., and Haegert D.G. Altered naive CD4 and CD8 T cell homeostasis in patients with relapsing-remitting multiple sclerosis: thymic versus peripheral (non-thymic) mechanisms. Clin. Exp. Immunol. 143 (2006) 305-313
10. Farina C., Weber M.S., Meinl E., Wekerle H., and Hohlfeld R. Glatiramer acetate in multiple sclerosis: update on potential mechanisms of action. Lancet Neurol. 4 (2005) 567-575
11. Fellay B., Chofflon M., Juillard C., Paunier A.M., Landis T., Roth S., and Gougeon M.L. Beneficial effect of co-polymer 1 on cytokine production by CD4 T cells in multiple sclerosis. Immunology 104 (2001) 383-391
12. Gran B., Tranquill L.R., Chen M., Bielekova B., Zhou W., Dhib-Jalbut S., and Martin R. Mechanisms of immunomodulation by glatiramer acetate. Neurology 55 (2000) 1704-1714
13. Hafler D.A. Multiple sclerosis. J. Clin. Invest. 113 (2004) 788-794
14. Hamann D., Baars P.A., Rep M.H., Hooibrink B., Kerkhof-Garde S.R., Klein M.R., and van Lier R.A. Phenotypic and functional separation of memory and effector human CD8+ T cells. J. Exp. Med. 186 (1997) 1407-1418
15. Hartung H.P., Bar-Or A., and Zoukos Y. What do we know about the mechanism of action of disease-modifying treatments in MS?. J. Neurol 251 Suppl. 5 (2004) v12-v29
16. Hemmer B., Archelos J.J., and Hartung H.P. New concepts in the immunopathogenesis of multiple sclerosis. Nat. Rev. Neurosci. 3 (2002) 291-301
17. Hemmer B., Kieseier B., Cepok S., and Hartung H.P. New immunopathologic insights into multiple sclerosis. Curr. Neurol. Neurosci. Rep. 3 (2003) 246-255
18. Hug A., Korporal M., Schroder I., Haas J., Glatz K., Storch-Hagenlocher B., and Wildemann B. Thymic export function and T cell homeostasis in patients with relapsing remitting multiple sclerosis. J. Immunol. 171 (2003) 432-437
19. Karandikar N.J., Crawford M.P., Yan X., Ratts R.B., Brenchley J.M., Ambrozak D.R., Lovett-Racke A.E., Frohman E.M., Stastny P., Douek D.C., Koup R.A., and Racke M.K. Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis. J. Clin. Invest. 109 (2002) 641-649
20. Khoury S.J., Guttmann C.R., Orav E.J., Kikinis R., Jolesz F.A., and Weiner H.L. Changes in activated T cells in the blood correlate with disease activity in multiple sclerosis. Arch. Neurol. 57 (2000) 1183-1189
21. Ledru E., Lecoeur H., Garcia S., Debord T., and Gougeon M.L. Differential susceptibility to activation-induced apoptosis among peripheral Th1 subsets: correlation with Bcl-2 expression and consequences for AIDS pathogenesis. J. Immunol. 160 (1998) 3194-3206
22. Liu J., Marino M.W., Wong G., Grail D., Dunn A., Bettadapura J., Slavin A.J., Old L., and Bernard C.C. TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination. Nat. Med. 4 (1998) 78-83
23. Martino G., and Hartung H.P. Immunopathogenesis of multiple sclerosis: the role of T cells. Curr. Opin. Neurol. 12 (1999) 309-321
24. Martino G., Adorini L., Rieckmann P., Hillert J., Kallmann B., Comi G., and Filippi M. Inflammation in multiple sclerosis: the good, the bad, and the complex. Lancet Neurol. 1 (2002) 499-509
25. Matusevicius D., Navikas V., Soderstrom M., Xiao B.G., Haglund M., Fredrikson S., and Link H. Multiple sclerosis: the proinflammatory cytokines lymphotoxin-alpha and tumour necrosis factor-alpha are upregulated in cerebrospinal fluid mononuclear cells. J. Neuroimmunol. 66 (1996) 115-123
26. Moller B.K., Andresen B.S., Christensen E.I., and Petersen C.M. Surface membrane CD4 turnover in phorbol ester stimulated T-lymphocytes. Evidence of degradation and increased synthesis. FEBS Lett. 276 (1990) 59-62
27. Muraro P.A., Pette M., Bielekova B., McFarland H.F., and Martin R. Human autoreactive CD4+ T cells from naive CD45RA+ and memory CD45RO+ subsets differ with respect to epitope specificity and functional antigen avidity. J. Immunol. 164 (2000) 5474-5481
28. Navikas V., and Link H. Review: cytokines and the pathogenesis of multiple sclerosis. J. Neurosci. Res. 45 (1996) 322-333
29. Neuhaus O., Farina C., Yassouridis A., Wiendl H., Then B.F., Dose T., Wekerle H., and Hohlfeld R. Multiple sclerosis: comparison of copolymer-1-reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 7452-7457
30. Neuhaus O., Farina C., Wekerle H., and Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology 56 (2001) 702-708
31. O'Connor K.C., Bar-Or A., and Hafler D.A. The neuroimmunology of multiple sclerosis: possible roles of T and B lymphocytes in immunopathogenesis. J. Clin. Immunol. 21 (2001) 81-92
32. O'Neil-Andersen N.J., and Lawrence D.A. Differential modulation of surface and intracellular protein expression by T cells after stimulation in the presence of monensin or brefeldin A. Clin. Diagn. Lab. Immunol. 9 (2002) 243-250
33. Petersen C.M., Christensen E.I., Andresen B.S., and Moller B.K. Internalization, lysosomal degradation and new synthesis of surface membrane CD4 in phorbol ester-activated T-lymphocytes and U-937 cells. Exp. Cell Res. 201 (1992) 160-173
34. Picker L.J., Singh M.K., Zdraveski Z., Treer J.R., Waldrop S.L., Bergstresser P.R., and Maino V.C. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood 86 (1995) 1408-1419
35. Poser C.M., Paty D.W., Scheinberg L., McDonald W.I., Davis F.A., Ebers G.C., Johnson K.P., Sibley W.A., Silberberg D.H., and Tourtellotte W.W. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann. Neurol. 13 (1983) 227-231
36. Racke M.K., Bonomo A., Scott D.E., Cannella B., Levine A., Raine C.S., Shevach E.M., and Rocken M. Cytokine-induced immune deviation as a therapy for inflammatory autoimmune disease. J Exp. Med. 180 (1994) 1961-1966
37. Rose J.W., Watt H.E., White A.T., and Carlson N.G. Treatment of multiple sclerosis with an anti-interleukin-2 receptor monoclonal antibody. Ann. Neurol. 56 (2004) 864-867
38. Sharief M.K., and Thompson E.J. Correlation of interleukin-2 and soluble interleukin-2 receptor with clinical activity of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 56 (1993) 169-174
39. *. Annu. Rev. Immunol. 23 (2005) 683-747
40. Steinman L. Multiple sclerosis: a coordinated immunological attack against myelin in the central nervous system. Cell 85 (1996) 299-302
41. Vieira P.L., Heystek H.C., Wormmeester J., Wierenga E.A., and Kapsenberg M.L. Glatiramer acetate (copolymer-1, Copaxone) promotes Th2 cell development and increased IL-10 production through modulation of dendritic cells. J. Immunol. 170 (2003) 4483-4488
42. Weber M.S., Starck M., Wagenpfeil S., Meinl E., Hohlfeld R., and Farina C. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain 127 (2004) 1370-1378
43. Wiesemann E., Klatt J., Sonmez D., Blasczyk R., Heidenreich F., and Windhagen A. Glatiramer acetate (GA) induces IL-13/IL-5 secretion in naive T cells. J. Neuroimmunol. 119 (2001) 137-144
44. Zhang J., Markovic-Plese S., Lacet B., Raus J., Weiner H.L., and Hafler D.A. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 179 (1994) 973-984
45. Ziemssen T., Kumpfel T., Klinkert W.E., Neuhaus O., and Hohlfeld R. Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor. Brain 125 (2002) 2381-2391